Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis: A prospective, controlled pilot study
References (34)
- et al.
Rates of cancellous bone remodelling and turnover in osteopenia associated with primary biliary cirrhosis
Bone
(1993) - et al.
A controlled trial of prednisolone treatment in primary biliary cirrhosis; three year results
J Hepatol
(1992) - et al.
Four-year study of intermittent cyclic etidronate treatment of post-menopausal osteoporosis: three years of blinded therapy followed by one year of open therapy
Am J Med
(1993) - et al.
Prevention of steroid induced osteoporosis with (3-amino-1-hydroxypropylididene)-,1-bisphosphonate (APD)
Lancet
(1988) - et al.
Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women
Am J Med
(1995) - et al.
Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis
Am J Med
(1995) - et al.
Glucocorticoid-induced osteoporosis
Clin Rheum Dis
(1986) Primary biliary cirrhosis and bone disease
Hepatology
(1995)- et al.
Bone mass in women with primary biliary cirrhosis; the relation with histological stage and use of corticosteroids
Gastroenterology
(1990) - et al.
Bone loss in autoimmune chronic active hepatitis on maintenance corticosteroid therapy
Gastroenterology
(1985)
Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference
Hepatology
(1995)
Interpreting trials of bone-active agents
Am J Med
(1995)
Bone loss in response to long term glucocorticoid therapy
Bone Miner
(1990)
Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis
Hepatology
(1991)
Combined treatment with ursodeoxycholic acid and prednisone in primary biliary cirrhosis
Neth J Med
(1994)
A randomized, placebo-controlled trial with prednisone/azathioprine in addition to ursodeoxycholic acid in primary biliary cirrhosis [Abstract]
J Hepatol
(1994)
Cited by (121)
The Impact of Tenofovir Disoproxil Fumarate on Reduced Bone Mineral Density and Fractures in Liver Transplant Recipients
2021, Transplantation ProceedingsGlucocorticoid-induced osteoporosis and Cushing’s syndrome
2020, Marcus and Feldman’s OsteoporosisEASL Clinical Practice Guidelines on nutrition in chronic liver disease
2019, Journal of HepatologyGlucocorticoid-Induced Osteoporosis
2013, Osteoporosis: Fourth EditionOsteoporosis in liver cirrhosis
2012, Gastroenterologia y HepatologiaThe Pharmacologic Management of Osteoporosis in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis
2020, Journal of Clinical DensitometryCitation Excerpt :Of the 435 screened studies, 11 studies met inclusion criteria (Supplementary Fig. 1). Three were RCT's evaluating bisphosphonates [2 etidronate, 1 alendronate] (5,13,14) and 2 evaluating HRT (8,15). One each assessed ursodeoxycholic acid (UDCA) (17), obeticholic acid (OCA) (18), cyclosporine A (CsA) (7), vitamin K (19), calcitriol (20), and sodium fluoride (6).
Copyright © 1997 Published by Elsevier Ireland Ltd.